{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T11:57:42Z","timestamp":1725969462206},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.2165\/11207000-000000000-00000","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T21:18:26Z","timestamp":1362518306000},"page":"235-238","source":"Crossref","is-referenced-by-count":1,"title":["Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males"],"prefix":"10.1007","volume":"12","author":[{"given":"Karly P.","family":"Garnock-Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna R.","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,23]]},"reference":[{"issue":"5","key":"12040235_CR1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/11205980-000000000-00000","volume":"71","author":"KP Garnock-Jones","year":"2011","unstructured":"Garnock-Jones KP, Giuliano AR. Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine for the prevention of genital warts in males. Drugs 2011; 71(5): 591\u2013602","journal-title":"Drugs"},{"issue":"22","key":"12040235_CR2","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.2146\/ajhp070627","volume":"65","author":"DJ Hutchinson","year":"2008","unstructured":"Hutchinson DJ, Klein KC. Human papillomavirus disease and vaccines. Am J Health Syst Pharm 2008 Nov 15; 65(22): 2105\u201312","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"12040235_CR3","first-page":"101","volume":"42","author":"PR Hsueh","year":"2009","unstructured":"Hsueh PR. Human papillomavirus, genital warts, and vaccines. J Microbiol Immunol Infect 2009 Apr; 42(2): 101\u20136","journal-title":"J Microbiol Immunol Infect"},{"issue":"4","key":"12040235_CR4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1158\/1055-9965.EPI-07-0741","volume":"17","author":"AR Giuliano","year":"2008","unstructured":"Giuliano AR, Salmon D. The case for a gender-neutral (universal) human papillomavirus vaccination policy in the United States: point. Cancer Epidemiol Biomarkers Prev 2008; 17(4): 805\u20139","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"Suppl. 10","key":"12040235_CR5","doi-asserted-by":"crossref","first-page":"K17","DOI":"10.1016\/j.vaccine.2008.06.021","volume":"26","author":"AR Giuliano","year":"2008","unstructured":"Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008; 26 Suppl. 10: K17\u201328","journal-title":"Vaccine"},{"issue":"10","key":"12040235_CR6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jcp.2008.063149","volume":"62","author":"C Miralles-Guri","year":"2009","unstructured":"Miralles-Guri C, Bruni L, Cubilla AL, et al. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009 Oct; 62(10): 870\u20138","journal-title":"J Clin Pathol"},{"issue":"6","key":"12040235_CR7","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/OLQ.0b013e318198de8c","volume":"36","author":"EV Kliewer","year":"2009","unstructured":"Kliewer EV, Demers AA, Elliott L, et al. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. Sex Transm Dis 2009; 36(6): 380\u20136","journal-title":"Sex Transm Dis"},{"issue":"Suppl. 3","key":"12040235_CR8","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.vaccine.2006.06.015","volume":"24","author":"CJ Lacey","year":"2006","unstructured":"Lacey CJ, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions. HPV-6\/11 disease. Vaccine 2006 Aug; 24 Suppl. 3: S35\u201341","journal-title":"Vaccine"},{"key":"12040235_CR9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1471-2334-8-76","volume":"8","author":"P Hillemanns","year":"2008","unstructured":"Hillemanns P, Breugelmans JG, Gieseking F, et al. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis 2008; 8: 76","journal-title":"BMC Infect Dis"},{"issue":"8","key":"12040235_CR10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/OLQ.0b013e3181a74c2c","volume":"36","author":"SC Woodhall","year":"2009","unstructured":"Woodhall SC, Jit M, Cai C, et al. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. Sex Transm Dis 2009 Aug; 36(8): 515\u201321","journal-title":"Sex Transm Dis"},{"key":"12040235_CR11","unstructured":"Merck and Co. Gardasil\u00ae (human papillomavirus quadrivalent [types 6, 11, 16, and 18] vaccine, recombinant, intramuscular injection): US prescribing information [online]. Available from URL: http:\/\/www.merck.com\/product\/usa\/pi_circulars\/g\/gardasil\/gardasil_pi.pdf [Accessed 2010 May 28]"},{"issue":"Suppl. 4","key":"12040235_CR12","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jadohealth.2010.01.010","volume":"46","author":"JM Palefsky","year":"2010","unstructured":"Palefsky JM. Human papillomavirus-related disease in men: not just a women\u2019s issue [published erratum appears in J Adolesc Health 2010; 46: 614]. J Adolesc Health 2010; 46 Suppl. 4: S12\u20139","journal-title":"J Adolesc Health"},{"key":"12040235_CR13","unstructured":"Australian Government, Department of Health and Ageing, Therapeutic Goods Administration. Gardasil (human papillomavirus vaccine) [online]. Available from URL: http:\/\/www.tga.gov.au\/safety\/alerts-medicine-gardasil-070624.htm [Accessed 2012 Aug 20]"},{"key":"12040235_CR14","doi-asserted-by":"crossref","first-page":"a769","DOI":"10.1136\/bmj.a769","volume":"337","author":"M Jit","year":"2008","unstructured":"Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337: a769","journal-title":"BMJ"},{"issue":"8","key":"12040235_CR15","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/ijc.23633","volume":"123","author":"MA Smith","year":"2008","unstructured":"Smith MA, Canfell K, Brotherton JML, et al. The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer 2008; 123(8): 1854\u201363","journal-title":"Int J Cancer"},{"issue":"7","key":"12040235_CR16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/sti.2009.037788","volume":"85","author":"CK Fairley","year":"2009","unstructured":"Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009 Dec; 85(7): 499\u2013502","journal-title":"Sex Transm Infect"},{"issue":"11","key":"12040235_CR17","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/OLQ.0b013e3181e71069","volume":"37","author":"M Heiligenberg","year":"2010","unstructured":"Heiligenberg M, Michael KM, Kramer MA, et al. Seroprevalence and determinants of eight high-risk human papillomavirus types in homosexual men, heterosexual men, and women: a population-based study in Amsterdam. Sex Transm Dis 2010 Aug 19; 37(11): 672\u201380","journal-title":"Sex Transm Dis"},{"issue":"32","key":"12040235_CR18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0968-8080(08)32413-6","volume":"16","author":"T Kubba","year":"2008","unstructured":"Kubba T. Human papillomavirus vaccination in the United Kingdom: what about boys? Reprod Health Matters 2008 Nov; 16(32): 97\u2013103","journal-title":"Reprod Health Matters"},{"key":"12040235_CR19","doi-asserted-by":"crossref","first-page":"b3884","DOI":"10.1136\/bmj.b3884","volume":"339","author":"JJ Kim","year":"2009","unstructured":"Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339: b3884","journal-title":"BMJ"},{"issue":"42","key":"12040235_CR20","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","volume":"28","author":"EH Elbasha","year":"2010","unstructured":"Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010 Oct; 28(42): 6858\u201367","journal-title":"Vaccine"},{"issue":"12","key":"12040235_CR21","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1473-3099(10)70219-X","volume":"10","author":"JJ Kim","year":"2010","unstructured":"Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010 Dec; 10(12): 845\u201352","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"12040235_CR22","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1542\/peds.2006-0461","volume":"118","author":"SL Block","year":"2006","unstructured":"Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006 Nov; 118(5): 2135\u201345","journal-title":"Pediatrics"},{"issue":"3","key":"12040235_CR23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","volume":"26","author":"KS Reisinger","year":"2007","unstructured":"Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007 Mar; 26(3): 201\u20139","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"12040235_CR24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","volume":"354","author":"AR Giuliano","year":"2011","unstructured":"Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011 Feb; 354(5): 401\u2013411. Plus supplementary material available from URL: http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa0909537 [Accessed 2011 Feb 4]","journal-title":"N Engl J Med"},{"key":"12040235_CR25","unstructured":"US FDA. Clinical review of biologics license application supplement STN# 125126\/1297.0: male indication for GARDASIL [online]. Available from URL: http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM190977.pdf [Accessed 2010 Jun 1]"},{"issue":"4","key":"12040235_CR26","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/INF.0b013e3181c177fb","volume":"29","author":"T Vesikari","year":"2010","unstructured":"Vesikari T, Van Damme P, Lindblad N, et al. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6\/11\/16\/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J 2010 Apr; 29(4): 314\u20138","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"12040235_CR27","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1542\/peds.2009-2336","volume":"125","author":"KS Reisinger","year":"2010","unstructured":"Reisinger KS, Block SL, Collins-Ogle M, et al. Safety, tolerability, and immunogenicity of Gardasil given concomitantly with Menactra and Adacel. Pediatrics 2010; 125(6): 1142\u201351","journal-title":"Pediatrics"},{"issue":"18","key":"12040235_CR28","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1016\/j.vaccine.2010.02.045","volume":"28","author":"A Arguedas","year":"2010","unstructured":"Arguedas A, Soley C, Loaiza C, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 2010 Apr 19; 28(18): 3171\u20139","journal-title":"Vaccine"},{"issue":"5","key":"12040235_CR29","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.vaccine.2007.11.043","volume":"26","author":"CM Wheeler","year":"2008","unstructured":"Wheeler CM, Bautista OM, Tomassini JE, et al. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6\/11\/16\/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008 Jan 30; 26(5): 686\u201396","journal-title":"Vaccine"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2165\/11207000-000000000-00000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T04:36:26Z","timestamp":1644467786000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/11207000-000000000-00000"}},"subtitle":["Profile Report"],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["12040235"],"URL":"https:\/\/doi.org\/10.2165\/11207000-000000000-00000","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}